Fax: (314) 454-7551
Primary plasma cell leukemia
A Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004
Article first published online: 28 OCT 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 24, pages 5734–5739, 15 December 2009
How to Cite
Ramsingh, G., Mehan, P., Luo, J., Vij, R. and Morgensztern, D. (2009), Primary plasma cell leukemia. Cancer, 115: 5734–5739. doi: 10.1002/cncr.24700
- Issue published online: 2 DEC 2009
- Article first published online: 28 OCT 2009
- Manuscript Accepted: 20 APR 2009
- Manuscript Revised: 3 APR 2009
- Manuscript Received: 13 JAN 2009
- plasma cell leukemia;
- multiple myeloma;
- Surveillance, Epidemiology, and End Results Program;
- risk factors
Primary plasma cell leukemia (PCL) is a rare plasma cell disorder, and current knowledge regarding survival in this disease is limited to small series of patients. Although there has been significant improvement in the survival of patients with multiple myeloma (MM) over the past few decades, it is not known whether there has been a similar trend for PCL.
The authors analyzed the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the characteristics and survival of patients who had PCL compared with those of patients who had MM.
Among 291 patients with PCL, the median age was 67 years (range, 19-98 years), the distribution of men and women was nearly equal, and the majority of patients were white (79.4%). The median overall survival (OS) was 4 months and the median disease-specific survival (DSS) was 6 months for patients with PCL; the 1-year, 2-year, and 5-year OS rates were 27.8%, 14.1%, and 6.4%, respectively. There were no survival differences noted according to sex or race. Patients aged <60 years were found to have a better median OS compared with patients aged ≥60 years (median OS, 7 months vs 3 months; P = .007), although the 5-year OS was equally poor in both groups (6.3% vs 6.4%, respectively). During the same period, 49,106 patients with MM were identified. Unlike MM, in which there has been a modest but statistically significant improvement in OS and DSS noted over time, no significant improvement was evident for PCL.
The poor long-term outcome and the lack of survival improvement in PCL suggest the need for better therapeutic options for these patients. Cancer 2009. © 2009 American Cancer Society.